Mobility, Strength, and Functional Outcomes Before Surgery, at 3 Months, and at 6 Months After Hip Arthroscopy for Femoroacetabular Impingement Syndrome

Mobility, Strength, and Functional Outcomes Before Surgery, at 3 Months, and at 6 Months

The aim of this study is to identify the factors associated with successful rehabilitation following hip arthroscopy for femoroacetabular impingement syndrome and to highlight any persistent functional deficits at different key stages of rehabilitation. This is a controlled multi-observational study. The pathological hip of patients will be compared to their second healthy hip as well as to a healthy control group.

Assessments of mobility, strength, functional tests, and questionnaire submissions will take place before the intervention and 3 and 6 months after the intervention.

Study Overview

• Status: Recruiting
• Conditions: Healthy Participants; Femoroacetabular Impingement Syndrome

• Study Type: Observational
• Enrollment (Estimated): 60

Contacts and Locations

• Study Contact: Name: Raphaël Leroy, PT, PhD candidate; Phone Number: +32491128430; Email: rleroy@uliege.be

Study Locations

• Belgium
  • Liège
    • Sart Tilman, Liège, Belgium, 4000
      • Recruiting
      • Blanc Gravier sports centers
      • Contact: Raphaël Leroy, PT, PhD candidate; Phone Number: +32491128430; Email: rleroy@uliege.be

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Adults aged 18-40 years will be recruited. The patient group will include individuals diagnosed with femoroacetabular impingement syndrome who are scheduled to undergo hip arthroscopy by specialized surgeons. A healthy control group without a history of hip pathology will be recruited from the local community matched as closely as possible to the patient group for demographic parameters.

Description

Inclusion Criteria:

• Subjects with femoroacetabular impingement syndrome, with corresponding clinical symptoms and signs, as well as validation by imaging
• Subjects who have already consulted a surgeon specializing in hip arthroscopic surgery and whose surgery is planned to treat femoroacetabular impingement syndrome
• Subjects aged between 18 and 40

Exclusion Criteria:

• History of rheumatic disease, dysplasia or pediatric disease affecting the hip (Legg-Calvé; superior femoral epiphysiolysis)
• Subject who has already undergone surgery on the hip joint
• Subjects with a history of injury to the muscles involved in the assessments within the last year

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Patient groups: 30 subjects with femoroacetabular impingement syndrome
Control group : 30 subjects with healthy hips

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Muscle strength in Nm	Muscular strength is measured using a fixed dynamometer	Pre-intervention, at 3 months and 6 months post-intervention
Hip mobility in degree	Hip mobility is measured using an electronic goniometer	Pre-intervention, at 3 months and 6 months post-intervention
Functional results on the Y Balance Test	The functional results of the Y balance test will be measured using the composite score.	Pre-intervention, at 3 months and 6 months post-intervention
Functional results in the single-leg squat test	The functional results of the single-leg squat test will be measured using the SIngle-leg squat Movement Performance scaLe for Individuals with FemoroAcetabular Impingement syndrome (SIMPLAI-FAI). The score on this scale ranges from 0 to 8. A higher score indicates a better functional outcome.	Pre-intervention, at 3 months and 6 months post-intervention
Measurements of patient-reported outcomes using the Hip-Return to Sport After Injury Scale (HIP-RSI)	Analysis of scores obtained on the HIP-RSI questionnaire. This questionnaire assesses psychological readiness to resume sports activities following hip surgery. It consists of six items, and the final score ranges from 0 to 100. A higher score indicates greater psychological readiness to return to sports activities.	Pre-intervention, at 3 months and 6 months post-intervention
Measurements of patient-reported outcomes using the International Hip Outcome Tool-12 (iHot-12) questionnaire	Analysis of scores obtained on the iHot-12 questionnaire. This questionnaire assesses the quality of life of young, active patients suffering from hip problems. It consists of 12 items and the final score ranges from 0 to 100. A score of 100 indicates full function and no symptoms, whereas a score of zero signifies maximum limitations and extreme symptoms.	Pre-intervention, at 3 months and 6 months post-intervention

Collaborators and Investigators

• Sponsor: University of Liege

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2026
• Primary Completion (Estimated): June 30, 2027
• Study Completion (Estimated): June 30, 2027

Study Registration Dates

• First Submitted: March 5, 2026
• First Submitted That Met QC Criteria: March 11, 2026
• First Posted (Actual): March 16, 2026

Study Record Updates

• Last Update Posted (Actual): May 5, 2026
• Last Update Submitted That Met QC Criteria: April 28, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: mobility; Strength; Questionnaires; Femoroacetabular impingement syndrome; Physical impairments
• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Pathologic Processes; Joint Diseases; Pathological Conditions, Signs and Symptoms; Femoracetabular Impingement
• Other Study ID Numbers: 2026-063

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: The principal investigator behind the study project will be the only person to process the data collected during this study. There are no plans to share this data.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No